Interestingly, these events were differentially associated either with single-agent anti-PD-1/PD-L1 (myasthenia gravis and encephalitis) or anti-CTLA-4 (GBS and meningitis), and were generally increased by combination ICI therapy. This evidence concerns the gene CTLA4 and encephalitis.